trending Market Intelligence /marketintelligence/en/news-insights/trending/4wrfzna8w9gjwxg3k3opbq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Therapeutic Solutions to allow 'Right to Try' access for new cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Therapeutic Solutions to allow 'Right to Try' access for new cancer drug

Therapeutic Solutions International Inc. is planning to allow patients to access its immunotherapy drug StemVacs under the Right to Try Act after an early trial of the medicine showed safety in patients with advanced cancer.

The Oceanside, Calif.-based company said the immunotherapeutic cell-based drug StemVacs instructs the immune system to seek and destroy cancer stem cells, which are believed to be responsible for initiating the growth of tumors. Chief Medical Officer James Veltmeyer said, "to our knowledge, StemVacs is the only clinical stage immunotherapeutic that kills cancer stem cells."

The phase 1 trial, which included 10 patients with various types of advanced cancers, showed no treatment-associated adverse events. In some cases, stabilization of tumors and stimulation of immunity were observed.

The company said it plans to use the phase 1 data to allow patient access to the drug as soon as possible under the Right to Try Act. The act allows Americans with a life-threatening disease or condition to seek experimental treatments without having to go through the U.S. Food and Drug Administration's long-standing compassionate-use process.